Literature DB >> 23065517

Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Stephanie Beurlet1, Christine Chomienne, Rose Ann Padua.   

Abstract

Myelodysplastic syndromes represent particularly challenging hematologic malignancies that arise from a large spectrum of genetic events resulting in a disease characterized by a range of different presentations and outcomes. Despite efforts to classify and identify the key genetic events, little improvement has been made in therapies that will increase patient survival. Animal models represent powerful tools to model and study human diseases and are useful pre-clinical platforms. In addition to enforced expression of candidate oncogenes, gene inactivation has allowed the consequences of the genetic effects of human myelodysplastic syndrome to be studied in mice. This review aims to examine the animal models expressing myelodysplastic syndrome-associated genes that are currently available and to highlight the most appropriate model to phenocopy myelodysplastic syndrome disease and its risk of transformation to acute myelogenous leukemia.

Entities:  

Mesh:

Year:  2012        PMID: 23065517      PMCID: PMC3533655          DOI: 10.3324/haematol.2012.069385

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  143 in total

1.  Mammalian polycomb-mediated repression of Hox genes requires the essential spliceosomal protein Sf3b1.

Authors:  Kyoichi Isono; Yoko Mizutani-Koseki; Toshihisa Komori; Marion S Schmidt-Zachmann; Haruhiko Koseki
Journal:  Genes Dev       Date:  2005-03-01       Impact factor: 11.361

2.  Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

Authors:  Benjamin S Braun; Joehleen A Archard; Jessica A G Van Ziffle; David A Tuveson; Tyler E Jacks; Kevin Shannon
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

Review 3.  Mouse models of myelodysplastic syndromes.

Authors:  Sarah H Beachy; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 4.  Myelodysplastic syndromes: an update on molecular pathology.

Authors:  Mar Tormo; Isabel Marugán; Marisa Calabuig
Journal:  Clin Transl Oncol       Date:  2010-10       Impact factor: 3.405

5.  Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents.

Authors:  M K Andersen; D H Christiansen; M Kirchhoff; J Pedersen-Bjergaard
Journal:  Genes Chromosomes Cancer       Date:  2001-05       Impact factor: 5.006

6.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  Impaired myelopoiesis in mice devoid of interferon regulatory factor 1.

Authors:  U Testa; E Stellacci; E Pelosi; P Sestili; M Venditti; R Orsatti; A Fragale; E Petrucci; L Pasquini; F Belardelli; L Gabriele; A Battistini
Journal:  Leukemia       Date:  2004-11       Impact factor: 11.528

8.  Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer.

Authors:  Jun Gao; Jian Song; Haojie Huang; Zhaoshen Li; Yiqi Du; Jia Cao; Minghui Li; Shunli Lv; Han Lin; Yanfang Gong
Journal:  J Exp Clin Cancer Res       Date:  2010-03-26

9.  Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes.

Authors:  Xiao Shuai; Daobin Zhou; Ti Shen; Yongji Wu; Jieping Zhang; Xuan Wang; Qian Li
Journal:  Cancer Genet Cytogenet       Date:  2009-10-15

10.  Impaired differentiation and apoptosis of hematopoietic precursors in a mouse model of myelodysplastic syndrome.

Authors:  Chul Won Choi; Yang Jo Chung; Christopher Slape; Peter D Aplan
Journal:  Haematologica       Date:  2008-07-04       Impact factor: 9.941

View more
  11 in total

Review 1.  Stem and progenitor cell alterations in myelodysplastic syndromes.

Authors:  Aditi Shastri; Britta Will; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

Review 2.  Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research.

Authors:  Ting Zhou; Marsha C Kinney; Linda M Scott; Sandra S Zinkel; Vivienne I Rebel
Journal:  Blood       Date:  2015-06-15       Impact factor: 22.113

Review 3.  Targeting Aberrant Splicing in Myelodysplastic Syndromes: Biologic Rationale and Clinical Opportunity.

Authors:  Andrew M Brunner; David P Steensma
Journal:  Hematol Oncol Clin North Am       Date:  2019-12-11       Impact factor: 3.722

4.  Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis.

Authors:  Jasmine C Wong; Kelley M Weinfurtner; Maria Del Pilar Alzamora; Scott C Kogan; Michael R Burgess; Yan Zhang; Joy Nakitandwe; Jing Ma; Jinjun Cheng; Shann-Ching Chen; Theodore T Ho; Johanna Flach; Damien Reynaud; Emmanuelle Passegué; James R Downing; Kevin Shannon
Journal:  Elife       Date:  2015-07-20       Impact factor: 8.140

5.  The orphan nuclear receptor EAR-2 (NR2F6) inhibits hematopoietic cell differentiation and induces myeloid dysplasia in vivo.

Authors:  Christine V Ichim; Dzana D Dervovic; Lap Shu Alan Chan; Claire J Robertson; Alden Chesney; Marciano D Reis; Richard A Wells
Journal:  Biomark Res       Date:  2018-12-07

6.  Novel spontaneous myelodysplastic syndrome mouse model.

Authors:  Weisha Li; Lin Cao; Mengyuan Li; Xingjiu Yang; Wenlong Zhang; Zhiqi Song; Xinpei Wang; Lingyan Zhang; Grant Morahan; Chuan Qin; Ran Gao
Journal:  Animal Model Exp Med       Date:  2021-05-14

7.  Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity.

Authors:  Brian A Jonas; Carl Johnson; Dita Gratzinger; Ravindra Majeti
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

Review 8.  The complexity of epigenetic diseases.

Authors:  Ailbhe Jane Brazel; Douglas Vernimmen
Journal:  J Pathol       Date:  2015-11-17       Impact factor: 7.996

9.  GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.

Authors:  Laura Guerenne; Stéphanie Beurlet; Mohamed Said; Petra Gorombei; Carole Le Pogam; Fabien Guidez; Pierre de la Grange; Nader Omidvar; Valérie Vanneaux; Ken Mills; Ghulam J Mufti; Laure Sarda-Mantel; Maria Elena Noguera; Marika Pla; Pierre Fenaux; Rose Ann Padua; Christine Chomienne; Patricia Krief
Journal:  J Hematol Oncol       Date:  2016-01-27       Impact factor: 17.388

10.  JMJD1B Demethylates H4R3me2s and H3K9me2 to Facilitate Gene Expression for Development of Hematopoietic Stem and Progenitor Cells.

Authors:  Sihui Li; Shafat Ali; Xiaotao Duan; Songbai Liu; Juan Du; Changwei Liu; Huifang Dai; Mian Zhou; Lina Zhou; Lu Yang; Peiguo Chu; Ling Li; Ravi Bhatia; Dustin E Schones; Xiwei Wu; Hong Xu; Yuejin Hua; Zhigang Guo; Yanzhong Yang; Li Zheng; Binghui Shen
Journal:  Cell Rep       Date:  2018-04-10       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.